Survival of adult AML patients treated with chemotherapy in the U.S. population by age, race and ethnicity, sex, calendar-year period, and AML subgroup, 2001–2019

Martha S. Linet; Rochelle E. Curtis; Sara J. Schonfeld; Jacqueline B. Vo; Lindsay M. Morton; Graça M. Dores

doi:10.1016/j.eclinm.2024.102549

March 16, 2024EClinicalMedicineOpen Access

Survival of adult AML patients treated with chemotherapy in the U.S. population by age, race and ethnicity, sex, calendar-year period, and AML subgroup, 2001–2019

View Full Paper

Ask AI

Bookmark

Share

Abstract

This is the authors' abstract. We don't add key points for this paper.

Population-based survival studies of adult acute myeloid leukemia (AML) have not simultaneously evaluated age at diagnosis, race and ethnicity, sex, calendar period or AML subtypes/subgroups among chemotherapy-treated patients.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Linet et al. (2024) studied this question.

synapsesocial.com/papers/68e73b96b6db6435876b4f3f https://doi.org/10.1016/j.eclinm.2024.102549

View Full Paper

Ask AI

Bookmark

Share

Survival of adult AML patients treated with chemotherapy in the U.S. population by age, race and ethnicity, sex, calendar-year period, and AML subgroup, 2001–2019

Abstract

Ask about this paper

Discussion

Cite This Study

Survival of adult AML patients treated with chemotherapy in the U.S. population by age, race and ethnicity, sex, calendar-year period, and AML subgroup, 2001–2019

Abstract

Ask about this paper

Discussion

Cite This Study

Keep reading

Keep reading